First the US, now the EU: Pfizer’s 20-valent pneumococcal jab for infants headed to regulators
About five weeks after Pfizer said its 20-valent vaccine follow-up to Prevnar 13 was effective in infants in a US study, the Big Pharma now has the data from an EU late-stage trial that will send the jab to the continent’s regulators by year’s end.
Both the US and European Medicines Agency are expected to have the filings in hand for 20vPnC for infants before the first babies of 2023 are born. The US greenlit the vaccine, known as Prevnar 20, for adults in June 2021, and for the same population in the EU, where it’s known as Apexxnar, on Valentine’s Day of this year.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
